+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases



Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases



Gynecologic Oncology 116(1): 3-9



The literature shows that hyperglycosylated hCG is the invasion stimulus in malignant gestational trophoblastic diseases. The USA hCG Reference Service has characterized 2 gestational trophoblastic disease conditions marked by low proportion of hyperglycosylated hCG. These are quiescent gestational trophoblastic disease, defined as inactive or benign invasive disease, and minimally invasive gestational trophoblastic disease, defined as slow growing or chemorefractory disease with hCG increasing very slowly (doubling rate 2-6 weeks). Here we examine the USA hCG Reference Service experience with both diseases. Patient were referred to the USA hCG Reference Service, 133 cases shown to have quiescent gestational trophoblastic disease, 35 cases with aggressive and 30 with minimally invasive gestational trophoblastic disease. Quiescent or inactive gestational trophoblastic disease was demonstrated in 133 women. In 127 of these cases, no hyperglycosylated hCG was detected, and in 6 cases 4-27% hyperglycosylated hCG was detected. This is quiescent or inactive disease. Only 1 of 35 cases with aggressive gestational trophoblastic disease (>40% hyperglycosylated hCG) was chemorefractory. In contrast, 30 of 30 minimally invasive cases (<40% hyperglycosylated hCG) were chemorefractory. In chemorefractory cases hyperglycosylated hCG ranged from <1% to 39% of total hCG. The USA hCG Reference Service showed that proportions hyperglycosylated hCG significantly increases as total hCG rises. They recommended in minimally invasive cases to wait to hCG was >3000 IU/L before commencing chemotherapy. This was successful in 10 of 10 minimally invasive cases. Measurement of hyperglycosylated hCG or invasiveness is a critical step in management of invasive gestational trophoblastic disease. Quiescent of inactive gestational trophoblastic disease requires no therapy. Minimally invasive disease in chemorefractory. The USA hCG Reference Service experience suggests waiting until hCG exceeds 3000 IU/L before commencing any chemotherapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 053629056

Download citation: RISBibTeXText

PMID: 19822356

DOI: 10.1016/j.ygyno.2009.09.028


Related references

Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. Gynecologic Oncology 102(2): 145-150, 2006

Proportion hyperglycosylated hCG: a new test for discriminating gestational trophoblastic diseases. International Journal of Gynecological Cancer 24(9): 1709-1714, 2015

Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecologic Oncology 102(2): 151-159, 2006

Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease. Current Obstetrics and Gynecology Reports 3: 84-90, 2014

Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. European Journal of Cancer 51(13): 1725-1731, 2016

EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. Journal of Reproductive Medicine 49(6): 443-446, 2004

Salvage surgery for chemorefractory gestational trophoblastic disease. Journal of Clinical Oncology 12(12): 2737-2742, 1994

Methotrexate combined chemotherapy for chemorefractory gestational trophoblastic tumour. Zhonghua Fu Chan Ke Za Zhi 34(2): 97-100, 2001

Trophoblastic gestational diseases. Triploid syndrome, perivillous trophoblastic hyperplasia, trophoblastic pseudotumor, trophoblastic microcarcinoma and carcinoma. Annales D'anatomie Pathologique 25(1): 13-38, 1980

Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecologic Oncology 56(3): 421-424, 1995

Combination chemotherapy with etoposide and cisplatin for high-risk, chemorefractory and recurrent gestational trophoblastic neoplasia. Zhonghua Fu Chan Ke Za Zhi 42(9): 595-599, 2007

Gestational trophoblastic disease: presentations from the XLVTH World Congress on Gestational Trophoblastic Diseases. Journal of Reproductive Medicine 53(7): 455-456, 2008

Gestational trophoblastic disease: presentations from the XVIIth World Congress on Gestational Trophoblastic Diseases. Journal of Reproductive Medicine 59(5-6): 187-187, 2014

Gestational trophoblastic disease. Presentations from the XVth World Congress on gestational trophoblastic diseases. Journal of Reproductive Medicine 55(5-6): 182-183, 2010

Gestational trophoblastic disease: Presentations from the XVIth World Congress on Gestational Trophoblastic Diseases. Journal of Reproductive Medicine 57(5-6): 187-188, 2012